{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:54:26Z","timestamp":1761843266625,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4430,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,12]]},"abstract":"<jats:p>Ifosfamide is an antineoplastic agent that requires hepatic activation to the cytotoxic active metabolite ifosforamide mustard. During metabolism, the byproduct, chloroacetaldehyde, which is structurally similar to both chloral hydrate and acetaldehyde, is produced. Secondary to its ability to cross the blood\u2010brain barrier, this metabolite may be responsible for the neurotoxicity observed with ifosfamide. Any case of suspected ifosfamide\u2010induced neurotoxicity, together with a decision to treat, must be determined on an individual patient basis. The differential diagnosis should include infection, laboratory abnormalities, and concomitant drugs. At this time, literature to support treatment modalities such as intravenous albumin and methylene blue is minimal.<\/jats:p>","DOI":"10.1592\/phco.19.18.1450.30906","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T05:52:53Z","timestamp":1083045173000},"page":"1450-1455","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Suspected Ifosfamide\u2010Induced Neurotoxicity"],"prefix":"10.1002","volume":"19","author":[{"given":"Jennette I.","family":"McVay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy Morgan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"558","volume-title":"Cancer chemotherapy handbook","author":"Dorr RT","year":"1994"},{"key":"e_1_2_1_3_2","first-page":"517","article-title":"Ifosfamide metabolism and pharmacokinetics","volume":"14","author":"Kaijser GP","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/106002809202600207","article-title":"Ifosfamide\u2010induced neurotoxicity: a case report and review of the literature","volume":"26","author":"Miller LJ","year":"1992","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_5_2","first-page":"157","article-title":"Pharmacokinetics of alkylating agents","volume":"17","author":"Lind MJ","year":"1993","journal-title":"Cancer Surv"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686020"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050463"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050411"},{"key":"e_1_2_1_9_2","first-page":"3247","article-title":"Pharmacokinetics of ifosfamide, and 2\u2010 and 3\u2010dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10 day continuous infusion of ifosfamide","volume":"16","author":"Kaijser GP","year":"1996","journal-title":"Anticancer Res"},{"key":"e_1_2_1_10_2","first-page":"391","article-title":"Ifosfamide\/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity","volume":"75","author":"Ghosn M.","year":"1988","journal-title":"Bull Cancer"},{"key":"e_1_2_1_11_2","first-page":"1946","article-title":"Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P\u2010450 inducers and autoinduction by oxazaphosphorines","volume":"57","author":"Chang TKH","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3.0.CO;2-#"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(94)90027-2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(91)90344-5"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(86)90368-8"},{"issue":"8","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.1990.8.8.1399","article-title":"Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors","volume":"8","author":"Pratt CB","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90053-8"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050102"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050720"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90077-1"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-199302000-00004"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.18.1450.30906","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.18.1450.30906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:45:23Z","timestamp":1761050723000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.18.1450.30906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["10.1592\/phco.19.18.1450.30906"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.18.1450.30906","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1999,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}